It depends on the standard you follow. As of September 2026, Alnylam Pharmaceuticals, Inc. (ALNY) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones Islamic, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 3.41% / 30% · (Cash+Inv) / Mkt Cap (36m) 12.1% / 30% · Interest income / Revenue 2.12% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 3.41% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 12.1% / 33% · Receivables / Mkt Cap (36m) 3.65% / 49% · Interest income / Revenue 2.12% / 5% | Pass |
| Dow Jones Islamic | Debt / Mkt Cap (24m) 3.41% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 12.1% / 33.33% · Receivables / Mkt Cap (24m) 3.65% / 33.33% · Interest income / Revenue 2.12% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 17.1% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 54.2% / 33.33% · Receivables / Avg Assets (4Q) 15.5% / 33.33% · Interest income / Revenue 2.12% / 5% | Fail |
| FTSE | Debt / Total Assets 12.7% / 33.33% · (Cash+ST Inv) / Total Assets 44.9% / 33.33% · (Cash+Recv) / Total Assets 58.4% / 33.33% · Interest income / Revenue 2.12% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Alnylam Pharmaceuticals, Inc. (ALNY) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones Islamic, and fails MSCI and FTSE.
Yes. Alnylam Pharmaceuticals, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 2.12% of each dividend: Alnylam Pharmaceuticals, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is a Healthcare company (Biotechnology) with a market capitalization of $21.4B. The Maz Rating grades it against the other companies in its sector.
Alnylam Pharmaceuticals, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $159.73, Alnylam Pharmaceuticals, Inc. trades at 7.8x trailing earnings, 4.3x sales and 5.9x book value, with an EV/EBITDA of 16.7. Over the last twelve months it generated about $5.0B of revenue and $2.7B of net income. It runs a gross margin of 77.3%, an operating margin of 19.5% and a net margin of 54.3%. It shows return on equity of 159.7%, return on invested capital of 15.4% and a free cash flow yield of 2.3%. On the balance sheet: a debt-to-equity ratio of 0.35 and a current ratio of 2.48. Over the past 52 weeks the share price ranged from $149.18 to $479.79, with a beta of 0.27.
Alnylam Pharmaceuticals, Inc. does not currently pay a dividend.
52 Wall Street analyst ratings cover the stock: 37 Buy, 14 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commercial portfolio, the company maintains an active development pipeline. Key investigational therapies include givosiran, aimed at adolescent patients with AHP; patisiran, being explored for transthyretin amyloidosis (ATTR) with cardiomyopathy; cemdisiran for complement-mediated disorders; ALN-AAT02 for AAT deficiency-associated liver disease; ALN-HBV02 for chronic hepatitis B virus infection; Zilebesiran for hypertension; and ALN-HSD for non-alcoholic steatohepatitis (NASH). Additionally, other candidates such as Fitusiran for hemophilia and bleeding disorders, Inclisiran for hypercholesterolemia, an expanded indication for lumasiran for advanced PH1 and recurrent kidney stones, and vutrisiran for ATTR amyloidosis (currently in Phase 3 clinical trials) are also progressing. Alnylam also engages in strategic alliances with other pharmaceutical leaders. Notable collaborations include those with Regeneron Pharmaceuticals, Inc., focused on discovering and developing RNAi therapeutics for ocular and CNS targets, and with Sanofi Genzyme for broader RNAi therapeutic development and commercialization efforts. Further licensing and partnership agreements are in place with entities such as Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. Established in 2002, Alnylam Pharmaceuticals maintains its corporate headquarters in Cambridge, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.